Affymax (AFFY) +29.5% premarket after the FDA releases a favorable review of the company's...
Affymax (AFFY) +29.5% premarket after the FDA releases a favorable review of the company's application for its peginesatide drug, which treats anemia in patients with chronic kidney disease: "A favorable benefit-risk profile supports the approval of peginesatide... The availability of peginesatide would provide an important therapeutic option for dialysis patients in the U.S."
From other sites
at MarketWatch.com (Jun 3, 2013)
at CNBC.com (May 31, 2013)
at MarketWatch.com (Apr 2, 2013)
at MarketWatch.com (Mar 19, 2013)
at CNBC.com (Mar 19, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs